Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

ter of 2007 and $11.9 million in the fourth quarter of 2006. Net loss per common share for the fourth quarter of 2007 was $0.78, compared to $0.82 in the third quarter of 2007, and $0.54 in the fourth quarter of 2006.

As of December 31, 2007, Vanda's cash, cash equivalents, and marketable securities totaled approximately $93.2 million. As of December 31, 2007, the company had a total of approximately 26.6 million shares of common stock outstanding.

"I am extremely pleased with the successful submission and acceptance of the Fiapta(TM) NDA filing in 2007. This important achievement would not have been possible without the commitment and dedication of the Vanda team," stated Mihael Polymeropoulos, M.D., President and CEO of Vanda. "I am looking forward to an exciting 2008 during which we expect the results from our VEC-162 Phase III chronic insomnia clinical trial and the PDUFA action for Fiapta(TM)."

OPERATIONAL HIGHLIGHTS

Iloperidone

On September 27, 2007 Vanda announced that it had submitted an NDA to the U.S. Food and Drug Administration (FDA) for Fiapta(TM), its investigational atypical antipsychotic for the treatment of schizophrenia. On November 27, 2007 the company announced that the FDA had accepted and filed the NDA. Under the Prescription Drug User Fee Act (PDUFA) of 1992, Vanda expects a PDUFA action on or about July 27, 2008.

VEC-162

Vanda has completed enrollment for its VEC-162 Phase III chronic insomnia clinical trial. Vanda expects to report top-line results in June 2008. Vanda enrolled 324 patients in the trial, which is a randomized, double-blind, placebo-controlled 35-day study, measuring sleep onset and maintenance, as well as next-day performance.

FINANCIAL DETAILS

-- Operating Expenses. Fourth quarter 2007 R&D expenses, primarily

consisting of salaries and related costs of R&D personnel, stock-based

compensation, and the costs of consultants, materials and s
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... , June 19, 2013  Continuing its long ... infarction (MI), Beckman Coulter , Inc. announces the ... its new Access AccuTnI+3 troponin I assay for use ... "Clinicians have depended on Beckman Coulter,s troponin ... AccuTnI+3 assay has the proven performance to continue providing ...
(Date:6/19/2013)... June 19, 2013 ... presents Innovative Drug Delivery Systems: ... Licensing Opportunities for Generic Pharmaceutical ... There are more than ... drugs approved all over the ...
(Date:6/19/2013)... Earth, MN (PRWEB) June 19, 2013 ... of abuse tests, today announced that it has received ... to market and sell its DrugCheck® NxStep Onsite ... allows use of the rapid screening device in near-patient ... Onsite Drug Screen Cup received Health Canada Class III ...
(Date:6/18/2013)... New York, NY (PRWEB) June 18, 2013 ... technological innovation and sustainability, the Consulate General of Switzerland ... largest solar boat, Switzerland’s MS Tûranor PlanetSolar , ... as part of its DeepWater Expedition 2013 tour with ... catamaran, led by Capitain Gérard d’Aboville, runs exclusively on ...
Breaking Biology Technology:Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 2Innovative Drug Delivery Systems: Novel Product and Formulation Technology Licensing Opportunities for Generic Pharmaceutical Companies 3Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 2Express Diagnostics’ DrugCheck® On-site Test Cup Receives Health Canada Class III Medical Device Approval 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 2Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 3Switzerland’s MS Tûranor PlanetSolar, the World’s Largest Solar Boat, Arrives in New York City 4
... /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading ... that effective on March 16, 2009 the exercise term ... the holder to purchase one Class A common share ... extended from March 23, 2009 to December 31, 2009. ...
... Food Processing, Industry,VANCOUVER, March 2 ... "the Company") today announced that it has completed ... dehydration equipment to CAL-SAN Enterprises, Ltd. of Richmond, ... With this sale, EnWave has proven that it ...
... Part of "In the Zone for UC" Campaign, Centocor ... & Colitis Foundation of America for Each Point Pisani ... Centocor Ortho Biotech Inc. announced today a partnership with ... ulcerative colitis (UC) and funding to support continued education ...
Cached Biology Technology:BioMS Medical warrant extension 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 2EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 3EnWave Successfully Commercializes nutraREV(TM) Food Dehydration Technology 4Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 2Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 3Pro Hockey Player Fernando Pisani Looks to Shoot and Score Against Ulcerative Colitis 4
(Date:6/18/2013)... June 19, 2013  Paris Air Show – ... Test Systems) , a leading provider of innovative ... is demonstrating its solutions this week at the ... With growing challenges including increasingly complex armament systems ... feature-rich, specialized aerospace test solutions that address legacy ...
(Date:6/18/2013)... been awarded a $394,300 grant from the Tarrant ... flow in the new facilities of the 150-mile ... associate professor of civil engineering, will investigate the ... the water in an effort to eliminate biological ... Adding monochloramine is widely practiced throughout the United ...
(Date:6/18/2013)... Laboratory of Molecular Biology, has been honored as ... Award. Torrent is being recognized for his outstanding ... predict antimicrobial regions in proteins. Luis Rivas, Centro ... this algorithm to interrogate full genomes in order ... appealing results." , Torrent obtained his Ph.D. ...
Breaking Biology News(10 mins):Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2The American Society for Microbiology honors Marc Torrent 2
... Understanding the tens of thousands of proteins that compose the ... century, and research efforts to date have already enabled major ... potential avenues have been blocked by lack of information about ... bulk of these so far enigmatic proteins may now be ...
... Displays, Without Sacrificing Display Viewing QualityTHE WOODLANDS, Texas, ... UNXL), the developer of a unique new thin ... announced the availability of test samples for customers. ... to produce a transparent protective cover film that ...
... University of Pennsylvania has completed a research study begun in ... the northwest Atlantic Ocean around Mount Desert Island, Me., has ... during less than a century, providing a clear illustration of ... is published in the current issue of the Proceedings ...
Cached Biology News:New high-throughput screening technique makes probing puzzling proteins possible 2New high-throughput screening technique makes probing puzzling proteins possible 3New high-throughput screening technique makes probing puzzling proteins possible 4New high-throughput screening technique makes probing puzzling proteins possible 5UniPixel Announces Availability of Opcuity(TM) Finger Print Resistant Film Test Samples 2UniPixel Announces Availability of Opcuity(TM) Finger Print Resistant Film Test Samples 3Penn biologists demonstrate that size matters... in snail shells 2Penn biologists demonstrate that size matters... in snail shells 3
...
GLP expression profiling service on the Affymetrix platform. Starting material can be blood, tissue or RNA. 5 day turnaround. Standard and custom post analyses of microarray data available....
... Service enables early selection of the ... providing quantitative data for sensitivity, dynamic ... antibody. Furthermore quantitative antibody fingerprints can ... of your antibodies., The full-service package ...
... kit allows for rapid, convenient, and efficient ... bind/wash/elute process utilizes a spin column to ... for concentration of proteins which were electro-eluted ... strong ion exchangers, offering high binding capacity ...
Biology Products: